Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:9256
Name colorectal cancer
Definition A large intestine cancer that is located_in the colon and/or located_in the rectum.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 mutant PD0166285 colorectal cancer sensitive detail...
TP53 loss Ad5CMV-p53 gene colorectal cancer predicted - sensitive detail...
RET mutant Ponatinib colorectal cancer sensitive detail...
BRAF mutant MLN2480 colorectal cancer sensitive detail...
PIK3CA E542K PD-0325901 + Pictilisib colorectal cancer sensitive detail...
BRAF V600E Regorafenib colorectal cancer sensitive detail...
BRAF V600E Trametinib colorectal cancer sensitive detail...
BRAF V600E Sorafenib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib colorectal cancer sensitive detail...
BRAF V600E Lapatinib + Panobinostat colorectal cancer sensitive detail...
BRAF V600E Gefitinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Erlotinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Encorafenib colorectal cancer sensitive detail...
BRAF V600E Refametinib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + Panitumumab colorectal cancer sensitive detail...
PIK3CA E545K Dactolisib colorectal cancer sensitive detail...
APC inact mut Celecoxib + Erlotinib colorectal cancer sensitive detail...
APC inact mut Celecoxib colorectal cancer sensitive detail...
APC inact mut Sulindac colorectal cancer sensitive detail...
APC inact mut Erlotinib + Ibuprofen colorectal cancer sensitive detail...
APC inact mut Dasatinib colorectal cancer sensitive detail...
RET M918T Sorafenib colorectal cancer sensitive detail...
BRAF V600E Panitumumab + Vemurafenib colorectal cancer sensitive detail...
BRAF V600X Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E Selumetinib colorectal cancer sensitive detail...
APC inact mut XAV939 colorectal cancer sensitive detail...
APC inact mut PKF118-310 colorectal cancer sensitive detail...
APC inact mut CCT036477 colorectal cancer sensitive detail...
APC inact mut CCT070535 colorectal cancer sensitive detail...
APC inact mut CCT031374 colorectal cancer sensitive detail...
APC inact mut NC043 colorectal cancer sensitive detail...
CTNNB1 mutant BC21 colorectal cancer sensitive detail...
APC inact mut Pyrvinium colorectal cancer sensitive detail...
APC inact mut Niclosamide colorectal cancer sensitive detail...
NRAS wild-type Panitumumab colorectal cancer predicted - sensitive detail...
APC Q1338* JW67 colorectal cancer sensitive detail...
APC Q1338* JW74 colorectal cancer sensitive detail...
APC mutant JW74 colorectal cancer sensitive detail...
BRAF V600X Vemurafenib colorectal cancer no benefit detail...
BRAF V600X Cetuximab + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E CCT196969 colorectal cancer sensitive detail...
BRAF V600E CCT241161 colorectal cancer sensitive detail...
NRAS mutant Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer no benefit detail...
NRAS wild-type Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer predicted - sensitive detail...
PIK3CA H1047X Bevacizumab + Temsirolimus colorectal cancer predicted - resistant detail...
TP53 mutant Pazopanib + Vorinostat colorectal cancer sensitive detail...
PIK3CA R88Q Cetuximab + Floxuridine + Fluorouracil + Irinotecan colorectal cancer predicted - sensitive detail...
PIK3CA E542K Cetuximab + Irinotecan colorectal cancer predicted - sensitive detail...
PIK3CA E542V Cetuximab colorectal cancer predicted - sensitive detail...
PIK3CA E545K Cetuximab + Irinotecan colorectal cancer sensitive detail...
PIK3CA H1047R Cetuximab colorectal cancer sensitive detail...
FGFR2 amp Debio 1347 colorectal cancer sensitive detail...
APC mutant G-631 colorectal cancer no benefit detail...
MAP2K1 K57T Cetuximab colorectal cancer predicted - resistant detail...
MAP2K1 K57T Panitumumab colorectal cancer resistant detail...
MAP2K1 K57N Cetuximab colorectal cancer resistant detail...
MAP2K1 K57N Panitumumab colorectal cancer resistant detail...
MAP2K1 K57T Cetuximab + Trametinib colorectal cancer sensitive detail...
MAP2K1 K57N Cetuximab + Trametinib colorectal cancer sensitive detail...
MAP2K1 K57N Panitumumab + Trametinib colorectal cancer sensitive detail...
MAP2K1 K57T Panitumumab + Trametinib colorectal cancer sensitive detail...
BRAF V600E PIK3CA P449T Cetuximab colorectal cancer resistant detail...
BRAF V600E PIK3CA P449T Regorafenib colorectal cancer resistant detail...
BRAF V600E PIK3CA P449T Cetuximab + Regorafenib colorectal cancer sensitive detail...
BRAF V600E BI 882370 + Cetuximab colorectal cancer sensitive detail...
BRAF V600E Afatinib + BI 882370 colorectal cancer sensitive detail...
BRAF V600E BI 882370 + Trametinib colorectal cancer sensitive detail...
IDH1 R132H Metformin colorectal cancer sensitive detail...
IDH1 R132H AGI-5198 + Metformin colorectal cancer resistant detail...
IDH1 R132H AGI-5198 + Radiotherapy colorectal cancer resistant detail...
TP53 wild-type Prodigiosin colorectal cancer sensitive detail...
TP53 mutant Prodigiosin colorectal cancer sensitive detail...
TP53 loss Prodigiosin colorectal cancer sensitive detail...
BRAF V600E PD-0325901 colorectal cancer sensitive detail...
BRAF V600E SCH772984 colorectal cancer sensitive detail...
MLH1 inact mut N/A colorectal cancer not applicable detail...
FLT3 amp Sorafenib colorectal cancer predicted - sensitive detail...
MSH6 mutant N/A colorectal cancer not applicable detail...
BRAF V600E DT01 + Fluorouracil + Oxaliplatin colorectal cancer sensitive detail...
MAP2K1 F53L Trametinib colorectal cancer sensitive detail...
ATM loss Berzosertib colorectal cancer sensitive detail...
BRAF mutant Trametinib colorectal cancer resistant detail...
BRAF mutant Alpelisib + Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF G596R PIK3CA E545K Neratinib colorectal cancer sensitive detail...
APC mutant K-756 colorectal cancer predicted - sensitive detail...
BRAF V600E SHP099 colorectal cancer resistant detail...
BRAF V600E Vemurafenib colorectal cancer no benefit detail...
BRAF V600E Cetuximab + Selumetinib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Dabrafenib + Trametinib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D Cetuximab + Selumetinib colorectal cancer resistant detail...
BRAF V600E BRAF amp Cetuximab + Selumetinib colorectal cancer resistant detail...
BRAF V600E Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Dabrafenib colorectal cancer sensitive detail...
BRAF V600E Alpelisib + Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + SCH772984 colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + SCH772984 colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Dabrafenib + SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Dabrafenib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Alpelisib + Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Dabrafenib + SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Dabrafenib + SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 V211D Cetuximab + Encorafenib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D Dabrafenib + Trametinib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D Cetuximab + Dabrafenib + Trametinib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D SCH772984 colorectal cancer resistant detail...
BRAF V600E BRAF amp Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF V600E BRAF amp SCH772984 colorectal cancer resistant detail...
MAP2K1 F129L RO4927350 colorectal cancer sensitive detail...
BRAF V600E PLX7904 colorectal cancer sensitive detail...
BRAF V600E TAK-632 colorectal cancer sensitive detail...
BRAF V600E PLX4720 + TAK-632 colorectal cancer sensitive detail...
BRAF V600E BGB-283 colorectal cancer sensitive detail...
BRAF V600E BGB-283 + Cetuximab colorectal cancer sensitive detail...
BRAF V600E Pimasertib colorectal cancer sensitive detail...
BRAF V600E PIK3CA P449T Pimasertib colorectal cancer sensitive detail...
BRAF V600E Everolimus + Pimasertib colorectal cancer sensitive detail...
BRAF V600E PIK3CA P449T Everolimus + Pimasertib colorectal cancer sensitive detail...
BRAF V600E Pimasertib + Sorafenib colorectal cancer sensitive detail...
BRAF V600E PIK3CA P449T Pimasertib + Sorafenib colorectal cancer sensitive detail...
BRAF V600E Pimasertib + Regorafenib colorectal cancer sensitive detail...
BRAF V600E PIK3CA P449T Pimasertib + Regorafenib colorectal cancer sensitive detail...
TP53 mutant NSC59984 colorectal cancer predicted - sensitive detail...
TP53 R175L NSC59984 colorectal cancer sensitive detail...
TP53 R175H NSC59984 colorectal cancer sensitive detail...
TP53 R273H TP53 P309S NSC59984 colorectal cancer sensitive detail...
TP53 R273H TP53 P309S Cisplatin + NSC59984 colorectal cancer sensitive detail...
BRAF V600E PIK3CA P449T TP53 R273H PD-0325901 + Sapanisertib colorectal cancer sensitive detail...
BRAF V600E PIK3CA H1047R TP53 wild-type PD-0325901 + Sapanisertib colorectal cancer sensitive detail...
BRAF V600E PTEN loss TP53 wild-type PD-0325901 + Sapanisertib colorectal cancer sensitive detail...
TP53 wild-type PD-0325901 + Sapanisertib colorectal cancer predicted - sensitive detail...
PIK3CA mutant MS417 + Pictilisib colorectal cancer predicted - sensitive detail...
BRAF mutant PLX4720 colorectal cancer decreased response detail...
BRAF mutant AZ628 + Selumetinib colorectal cancer sensitive detail...
APC wild-type TASIN-1 colorectal cancer resistant detail...
APC inact mut TASIN-1 colorectal cancer sensitive detail...
APC E1309* TASIN-1 colorectal cancer sensitive detail...
APC E853* APC K1555* TASIN-1 colorectal cancer sensitive detail...
APC Q1131* APC Q1303* TASIN-1 colorectal cancer sensitive detail...
APC Q1338* TASIN-1 colorectal cancer sensitive detail...
APC L1488* TASIN-1 colorectal cancer sensitive detail...
APC G1416* TASIN-1 colorectal cancer sensitive detail...
FGFR2 over exp Aprutumab ixadotin colorectal cancer sensitive detail...
APC inact mut PTEN inact mut Dactolisib colorectal cancer sensitive detail...
APC inact mut PTEN inact mut Binimetinib colorectal cancer no benefit detail...
APC inact mut PTEN inact mut Binimetinib + Dactolisib colorectal cancer no benefit detail...
PIK3CA H1047R Metformin colorectal cancer sensitive detail...
BRAF mut TP53 wild-type CGM097 + Dabrafenib + Navitoclax + PF-04217903 colorectal cancer sensitive detail...
BRAF mut TP53 mut Alpelisib + Dabrafenib + Erlotinib + Navitoclax colorectal cancer sensitive detail...
TP53 loss Ceralasertib + Radiotherapy colorectal cancer sensitive detail...
BRAF act mut VX-11e + WEHI-539 colorectal cancer predicted - sensitive detail...
BRAF act mut Venetoclax + VX-11e colorectal cancer no benefit detail...
MAP2K1 F53L Cetuximab colorectal cancer resistant detail...
MAP2K1 C121S Cetuximab colorectal cancer resistant detail...
MAP2K1 F53L Cetuximab + Trametinib colorectal cancer sensitive detail...
MAP2K1 C121S Cetuximab + Trametinib colorectal cancer sensitive detail...
NRAS G12V Cetuximab + Trametinib colorectal cancer sensitive detail...
NRAS G12V Cetuximab colorectal cancer resistant detail...
TP53 loss PHA-680632 + Radiotherapy colorectal cancer sensitive detail...
BRAF mutant Binimetinib colorectal cancer predicted - sensitive detail...
APC S811* G007-LK colorectal cancer sensitive detail...
APC S1197* APC S1278* G007-LK colorectal cancer sensitive detail...
APC L665* APC R1450* G007-LK colorectal cancer resistant detail...
APC E853* APC T1556fs G007-LK colorectal cancer resistant detail...
APC N1819fs APC wild-type G007-LK colorectal cancer resistant detail...
APC S811* IWR-1 colorectal cancer sensitive detail...
APC S1197* APC S1278* IWR-1 colorectal cancer sensitive detail...
APC E853* APC T1556fs IWR-1 colorectal cancer resistant detail...
APC L665* APC R1450* IWR-1 colorectal cancer sensitive detail...
APC N1819fs IWR-1 colorectal cancer resistant detail...
APC S811* XAV939 colorectal cancer sensitive detail...
APC S1197* APC S1278* XAV939 colorectal cancer sensitive detail...
APC N1819fs APC wild-type XAV939 colorectal cancer resistant detail...
APC L665* APC R1450* XAV939 colorectal cancer sensitive detail...
APC E853* APC T1556fs XAV939 colorectal cancer resistant detail...
APC R216* G007-LK colorectal cancer sensitive detail...
APC R216* IWR-1 colorectal cancer sensitive detail...
APC I1164fs G007-LK colorectal cancer sensitive detail...
APC I1164fs IWR-1 colorectal cancer sensitive detail...
APC W553* IWR-1 colorectal cancer sensitive detail...
APC W553* G007-LK colorectal cancer sensitive detail...
TP53 wild-type MK-8745 colorectal cancer predicted - sensitive detail...
TP53 del TC-A2317 colorectal cancer predicted - sensitive detail...
IDH2 R172K Enasidenib colorectal cancer predicted - sensitive detail...
NRAS mut PIK3CA wild-type TAK-733 colorectal cancer predicted - sensitive detail...
BRAF mut PIK3CA wild-type TAK-733 colorectal cancer predicted - sensitive detail...
TP53 del Doxorubicin + Seliciclib colorectal cancer predicted - sensitive detail...
BRAF V600E PIK3CA mut ASN003 colorectal cancer sensitive detail...
TP53 wild-type ALRN-6924 colorectal cancer sensitive detail...
PTEN loss AZD8186 + Vistusertib colorectal cancer sensitive detail...
FGFR2 amp Erdafitinib colorectal cancer sensitive detail...
BRAF mutant Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF G596R Trametinib colorectal cancer sensitive detail...
BRAF G466V Cetuximab colorectal cancer sensitive detail...
BRAF G466V Trametinib colorectal cancer sensitive detail...
BRAF G466V Vemurafenib colorectal cancer predicted - resistant detail...
BRAF G466V Irinotecan + Panitumumab colorectal cancer predicted - sensitive detail...
BRAF G596R Vemurafenib colorectal cancer resistant detail...
BRAF mutant KO-947 colorectal cancer predicted - sensitive detail...
NRAS mutant KO-947 colorectal cancer predicted - sensitive detail...
PIK3CA K944N Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA V955G Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA V955I Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA K966E Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA E542K Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA E545K Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA H1047R Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA F930S Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA V952A Cetuximab + Fluorouracil colorectal cancer resistant detail...
BRAF G596R Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + PLX4720 colorectal cancer sensitive detail...
BRAF mutant Dabrafenib + Panitumumab + Trametinib colorectal cancer predicted - sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib colorectal cancer sensitive detail...
FBXW7 R505C Regorafenib colorectal cancer resistant detail...
BRAF V600E INU-152 colorectal cancer sensitive detail...
BRAF mutant LSN3074753 colorectal cancer predicted - sensitive detail...
BRAF V600E LSN3074753 colorectal cancer predicted - sensitive detail...
BRAF mutant Cetuximab + LSN3074753 colorectal cancer sensitive detail...
BRAF G596V NRAS G13R Cetuximab + LSN3074753 colorectal cancer sensitive detail...
BRAF V600E EBI-907 colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + Panitumumab + Trametinib colorectal cancer predicted - sensitive detail...
BRAF V600E Panitumumab + Trametinib colorectal cancer no benefit detail...
PIK3CA mutant Alpelisib colorectal cancer sensitive detail...
NRAS mutant SYM004 colorectal cancer predicted - resistant detail...
BRAF mutant SYM004 colorectal cancer predicted - resistant detail...
BRAF V600E Binimetinib + Cetuximab + Encorafenib colorectal cancer predicted - sensitive detail...
BRAF mutant Belvarafenib colorectal cancer sensitive detail...
NRAS mutant Regorafenib colorectal cancer no benefit detail...
BRAF mutant Regorafenib colorectal cancer no benefit detail...
BRAF V600E Ulixertinib colorectal cancer sensitive detail...
BRAF G596R RMC-4550 colorectal cancer predicted - sensitive detail...
TP53 R248Q Tanespimycin colorectal cancer sensitive detail...
TP53 del Tanespimycin colorectal cancer decreased response detail...
TP53 R248Q Napabucasin colorectal cancer predicted - sensitive detail...
BRAF V600E NRAS Q61K Panitumumab + Vemurafenib colorectal cancer predicted - resistant detail...
BRAF V600E BRAF amp Panitumumab + Vemurafenib colorectal cancer predicted - resistant detail...
BRAF V47_D380del BRAF V600E Alpelisib + Cetuximab + Encorafenib colorectal cancer predicted - resistant detail...
BRAF V600E NRAS G13R Alpelisib + Cetuximab + Encorafenib colorectal cancer predicted - resistant detail...
BRAF V600E NRAS amp Panitumumab + Vemurafenib colorectal cancer predicted - resistant detail...
BRAF V600E NRAS over exp Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF V600E NRAS over exp BGB659 + Cetuximab colorectal cancer sensitive detail...
BRAF V600E NRAS G13R BGB659 + Cetuximab colorectal cancer predicted - sensitive detail...
NRAS G12X Cetuximab colorectal cancer resistant detail...
NRAS G13X Cetuximab colorectal cancer resistant detail...
NRAS A59X Cetuximab colorectal cancer resistant detail...
NRAS Q61X Cetuximab colorectal cancer resistant detail...
NRAS K117X Cetuximab colorectal cancer resistant detail...
NRAS A146X Cetuximab colorectal cancer resistant detail...
NRAS A146X Panitumumab colorectal cancer resistant detail...
NRAS A59X Panitumumab colorectal cancer resistant detail...
NRAS G12X Panitumumab colorectal cancer resistant detail...
NRAS G13X Panitumumab colorectal cancer resistant detail...
NRAS K117X Panitumumab colorectal cancer resistant detail...
NRAS Q61X Panitumumab colorectal cancer resistant detail...
APC dec exp G007-LK colorectal cancer predicted - sensitive detail...
APC L852* G007-LK colorectal cancer predicted - resistant detail...
APC Q886* G007-LK colorectal cancer predicted - resistant detail...
CTNNB1 S33F G007-LK colorectal cancer predicted - resistant detail...
APC Q1406* G007-LK colorectal cancer predicted - sensitive detail...
APC E582fs G007-LK colorectal cancer predicted - resistant detail...
APC Q886* XAV939 colorectal cancer predicted - resistant detail...
APC Q1406* XAV939 colorectal cancer predicted - sensitive detail...
APC Q1406* NVP-TNKS656 colorectal cancer predicted - sensitive detail...
APC Q886* NVP-TNKS656 colorectal cancer predicted - resistant detail...
FGFR2 amp eFT226 colorectal cancer sensitive detail...
IDH1 R132H Talazoparib colorectal cancer predicted - sensitive detail...
IDH1 R132H Olaparib colorectal cancer predicted - sensitive detail...
FGFR2 amp Regorafenib colorectal cancer predicted - sensitive detail...
BRAF mutant SY-5609 colorectal cancer predicted - sensitive detail...
NRAS G115Efs*46 Cetuximab colorectal cancer predicted - resistant detail...
NRAS G115Efs*46 Panitumumab colorectal cancer predicted - resistant detail...
BRAF V600E Ravoxertinib colorectal cancer predicted - sensitive detail...
BRAF G596R PIK3CA E545K Vemurafenib colorectal cancer resistant detail...
BRAF V600E PIK3CA H1047R Vemurafenib colorectal cancer resistant detail...
BRAF V600E PIK3CA H1047R MK2206 + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E PIK3CA H1047R MK2206 colorectal cancer predicted - sensitive detail...
BRAF V600E Capecitabine + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Bevacizumab + Capecitabine + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Irinotecan + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Irinotecan + Vemurafenib colorectal cancer sensitive detail...
BRAF G596R PLX8394 colorectal cancer predicted - sensitive detail...
BRAF K601E PLX8394 colorectal cancer predicted - sensitive detail...
BRAF K601E Vemurafenib colorectal cancer resistant detail...
BRAF K601E Cetuximab colorectal cancer resistant detail...
BRAF K601E Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF K601E Cetuximab + PLX8394 colorectal cancer sensitive detail...
BRAF G466V PLX8394 colorectal cancer resistant detail...
BRAF G466V Cetuximab + PLX8394 colorectal cancer sensitive detail...
BRAF G466V Cetuximab + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E BI-3406 colorectal cancer predicted - resistant detail...
BRAF T119S BRAF V600E BI-3406 colorectal cancer predicted - resistant detail...
CDKN2A hypermethylation N/A colorectal cancer not applicable detail...
BRAF V600E Chloroquine + Trametinib colorectal cancer sensitive detail...
CTNNB1 T41A Cetuximab colorectal cancer resistant detail...
CTNNB1 S45F Cetuximab colorectal cancer resistant detail...
CTNNB1 S33P Cetuximab colorectal cancer resistant detail...
BRAF V600E unspecified immune checkpoint inhibitor colorectal cancer decreased response detail...
MSH6 loss unspecified immune checkpoint inhibitor colorectal cancer predicted - sensitive detail...
BRAF V600E BGB-283 + Trametinib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + Regorafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + RAF709 + Trametinib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + LXH 254 + Trametinib colorectal cancer sensitive detail...
NRAS G12D GI-4000 colorectal cancer predicted - sensitive detail...
BRAF V600E JSI-1187 colorectal cancer predicted - sensitive detail...
BRAF V600E Dabrafenib + JSI-1187 colorectal cancer predicted - sensitive detail...
NRAS Q61X Binimetinib colorectal cancer unknown detail...
NRAS Q61R Binimetinib colorectal cancer predicted - sensitive detail...
NRAS Q61K Binimetinib colorectal cancer predicted - sensitive detail...
BRAF V600E Belvarafenib colorectal cancer predicted - sensitive detail...
BRAF T119S BRAF V600E LY3214996 colorectal cancer predicted - sensitive detail...
MAP2K1 Q56P MAP2K1 H119Y MAP2K1 D351G LY3214996 colorectal cancer predicted - sensitive detail...
BRAF V600E LY3214996 colorectal cancer predicted - sensitive detail...
BRAF V600E ASN007 colorectal cancer sensitive detail...
MLH1 negative Pembrolizumab colorectal cancer sensitive detail...
MSH6 negative Pembrolizumab colorectal cancer sensitive detail...
MAP2K1 P124S Cetuximab + Irinotecan colorectal cancer predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00730158 Phase II Irinotecan YIV-906 A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer Completed USA 0
NCT00940316 Phase II Irinotecan Erlotinib + Panitumumab Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer Completed USA 0
NCT00940381 Phase I Cetuximab + Sirolimus Sirolimus and Cetuximab in Advanced Malignancies Completed USA 0
NCT00996892 Phase I Cobimetinib + Pictilisib Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors Terminated USA 0
NCT01006369 Phase II Hydroxychloroquine Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Completed USA 0
NCT01037790 Phase II Palbociclib PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Completed USA 0
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Suspended USA 0
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Terminated USA 0
NCT01260415 Phase II Panitumumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Fluorouracil + Irinotecan + Leucovorin A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases Completed CAN 0
NCT01294826 Phase I Cetuximab + Luminespib Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed USA 0
NCT01312857 Phase II Panitumumab Fluorouracil + Irinotecan + Leucovorin Floxuridine Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer Active, not recruiting USA 0
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Completed USA 2
NCT01340300 Phase II Metformin Exercise and Metformin in Colorectal and Breast Cancer Survivors Completed USA 0
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting USA 2
NCT01358331 Phase I MK-8353 A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) Terminated 0
NCT01436656 Phase I Encorafenib A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma Active, not recruiting 4
NCT01543698 Phase Ib/II Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors Active, not recruiting USA | CAN 7
NCT01562899 Phase II Binimetinib + Ganitumab A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors Terminated USA | CAN 6
NCT01569984 Phase II Bevacizumab Radiosensitization of AVASTIN; (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis Completed CAN 0
NCT01576666 Phase Ib/II Buparlisib + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed USA | CAN 6
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA 6
NCT01591421 Phase Ib/II Buparlisib + Panitumumab P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer. Completed CAN 0
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed USA | CAN 1
NCT01661972 Phase Ib/II Aflibercept + Capecitabine Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer Completed USA 0
NCT01669720 Phase II Aflibercept Adjuvant Aflibercept for Metastatic Colorectal Cancer Terminated USA 0
NCT01676714 Phase II Dovitinib Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Completed USA 0
NCT01703390 Phase II Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Biomarker Directed Treatment in Metastatic Colorectal Cancer Completed 1
NCT01719380 Phase Ib/II Cetuximab + Encorafenib Alpelisib + Cetuximab + Encorafenib Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Completed USA | CAN 10
NCT01722162 Phase II Bevacizumab + Capecitabine Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer Completed USA 0
NCT01729923 Phase II Capecitabine Celecoxib A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer Terminated USA 0
NCT01750918 Phase II Fluorouracil Dabrafenib + Panitumumab Dabrafenib + Panitumumab + Trametinib Panitumumab + Trametinib BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) Completed USA 7
NCT01765582 Phase II Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer Terminated USA 0
NCT01776307 Phase II Cetuximab + Napabucasin Capecitabine + Napabucasin Napabucasin + Panitumumab A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer Completed USA 0
NCT01871311 Phase I Cetuximab + Nilotinib A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab Terminated USA 0
NCT01874860 Phase I Doxycycline Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients Recruiting USA 0
NCT01876511 Phase II Pembrolizumab Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors Completed USA 0
NCT01888965 Phase II Dovitinib Maintenance Dovitinib for Colorectal and Pancreas Cancer Terminated USA 0
NCT01923337 Phase I Alisertib + Irinotecan Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer Completed USA 0
NCT01927341 Phase Ib/II Binimetinib Panitumumab Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors Completed USA | CAN 5
NCT01937715 Phase II Bevacizumab Gedatolisib Fluorouracil + Irinotecan + Leucovorin A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer Terminated USA | CAN 1
NCT01939223 Phase III Regorafenib COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST) Terminated USA | CAN 12
NCT01952730 Phase I GVAX colorectal cancer vaccine GVAX for Colorectal Cancer Recruiting USA 0
NCT01960023 Phase Ib/II Cetuximab + Neratinib Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer Withdrawn USA 0
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA 2
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting USA | CAN 13
NCT01974258 Phase I Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn USA 0
NCT01988896 Phase I Atezolizumab + Cobimetinib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | CAN 4
NCT02004106 Phase I Cergutuzumab amunaleukin A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors Completed USA 7
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT02025803 Phase I Capecitabine + TAS-114 A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors Completed USA 0
NCT02038699 Phase Ib/II ONC201 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Withdrawn USA 0
NCT02041481 Phase I Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer Completed USA 0
NCT02060188 Phase Ib/II Nivolumab Ipilimumab A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) Active, not recruiting USA | CAN 6
NCT02083653 Phase II SYM004 Fluorouracil Capecitabine Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer Completed USA 9
NCT02110082 Phase I Cetuximab + Urelumab Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer Completed USA 0
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed 1
NCT02124148 Phase I Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed Disodium + Prexasertib LY3023414 + Prexasertib Fluorouracil + Leucovorin + Prexasertib A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer Completed USA 0
NCT02141295 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin RO5520985 Bevacizumab + Fluorouracil + Leucovorin Fluorouracil + Leucovorin + RO5520985 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE) Terminated USA 6
NCT02162563 Phase III Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (CAIRO5) Recruiting 2
NCT02168777 Phase Ib/II Refametinib + Regorafenib Refametinib Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer Terminated USA 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 3
NCT02199223 Phase I Panitumumab + Regorafenib Regorafenib + Panitumumab Terminated USA 0
NCT02205398 Phase Ib/II Capmatinib + Cetuximab Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy Terminated USA | CAN 5
NCT02227667 Phase II Durvalumab Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer Completed USA 0
NCT02260440 Phase II Azacitidine + Pembrolizumab A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer Completed USA 0
NCT02268825 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers Terminated USA 0
NCT02277093 Phase II Pacritinib Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer Terminated USA 0
NCT02278133 Phase Ib/II Cetuximab + Encorafenib + LGK974 Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations Completed USA | CAN 8
NCT02279433 Phase I DS6051b A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Completed USA 0
NCT02287025 FDA approved Regorafenib A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes? Terminated USA 0
NCT02298959 Phase I Aflibercept + Pembrolizumab Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors Recruiting USA | CAN 0
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Completed 1
NCT02316340 Phase II Vorinostat Hydroxychloroquine Regorafenib Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer Completed USA 0
NCT02318901 Phase Ib/II Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Terminated USA 0
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Completed USA 1
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed USA 0
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated USA 1
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated USA 1
NCT02399943 Phase II Panitumumab + Trametinib A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer Active, not recruiting CAN 0
NCT02402036 Phase II Regorafenib A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer Terminated USA 0
NCT02425683 Phase II Regorafenib Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX Terminated USA 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Unknown status USA 0
NCT02437071 Phase II Pembrolizumab Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients Active, not recruiting USA 0
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated USA 0
NCT02448810 Phase II Fluorouracil + Leucovorin Imalumab Panitumumab Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer Terminated USA 0
NCT02460198 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) Completed 0
NCT02460224 Phase Ib/II LAG525 Spartalizumab Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Completed USA | CAN 10
NCT02512172 Phase I Azacitidine + Pembrolizumab Pembrolizumab + Romidepsin Azacitidine + Pembrolizumab + Romidepsin A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer Active, not recruiting USA 0
NCT02516553 Phase I BI 894999 BI 894999 First in Human Dose Finding Study in Advanced Malignancies Active, not recruiting USA 5
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Completed USA 0
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed USA | CAN 2
NCT02538627 Phase I Seribantumab MM-151 Phase 1 Combination Study of MM-151 and MM-121 Terminated USA 0
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA 1
NCT02559024 Phase I MEDI6469 Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer Unknown status USA 0
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02563002 Phase III Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Active, not recruiting 0
NCT02568046 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin + SYM004 Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients Terminated USA 1
NCT02568267 Phase II Entrectinib Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) Recruiting USA 15
NCT02573220 Phase I Cetuximab + Fluorouracil + Irinotecan + Leucovorin Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer Withdrawn 1
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed 3
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Recruiting USA | CAN 29
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Terminated USA 0
NCT02599324 Phase Ib/II Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Completed USA 3
NCT02600949 Phase I Pembrolizumab Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma Recruiting USA 0
NCT02605044 Phase III Masitinib Fluorouracil + Irinotecan + Leucovorin Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer Terminated 3
NCT02613650 Phase I Binimetinib + Fluorouracil + Irinotecan + Leucovorin A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers Recruiting USA 0
NCT02630420 Phase I Cetuximab + Savolitinib Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer Withdrawn 0
NCT02632448 Phase Ib/II Gemcitabine + LY2880070 LY2880070 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Recruiting USA | CAN 0
NCT02636036 Phase I Enadenotucirev + Pembrolizumab Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors Active, not recruiting USA 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting USA 0
NCT02654639 Phase II Bevacizumab + Trifluridine-tipiracil hydrochloride Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer Terminated USA 0
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated USA 0
NCT02703571 Phase Ib/II Ribociclib + Trametinib Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors Terminated USA | CAN 5
NCT02713373 Phase Ib/II Cetuximab + Pembrolizumab Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT02713529 Phase Ib/II AMG 820 + Pembrolizumab Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer Completed USA | CAN 4
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Active, not recruiting USA | CAN 7
NCT02745769 Phase I Merestinib + Ramucirumab Abemaciclib + Ramucirumab A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents Completed USA 2
NCT02753127 Phase III Fluorouracil + Irinotecan + Leucovorin Napabucasin A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C) Completed USA | CAN 14
NCT02754856 Phase I Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases. Active, not recruiting USA 0
NCT02760797 Phase I Emactuzumab + Selicrelumab A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed USA 2
NCT02785068 Phase I Fluorouracil + Irinotecan + Leucovorin + MM-151 Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer Withdrawn 0
NCT02811497 Phase II Azacitidine + Durvalumab Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) Completed CAN 0
NCT02837263 Phase I Pembrolizumab PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Active, not recruiting USA 3
NCT02861300 Phase Ib/II Capecitabine + Telaglenastat CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer Suspended USA 0
NCT02870920 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies Active, not recruiting CAN 0
NCT02873195 Phase II Bevacizumab + Capecitabine Atezolizumab + Bevacizumab + Capecitabine Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Completed USA 0
NCT02888743 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT02890069 Phase I LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Active, not recruiting USA 6
NCT02900664 Phase I Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) Completed USA | CAN 7
NCT02906059 Phase I Adavosertib + Irinotecan Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Completed USA 0
NCT02928224 Phase III Cetuximab + Encorafenib Binimetinib + Cetuximab + Encorafenib Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC) Active, not recruiting USA | CAN 25
NCT02934529 Phase III Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Capecitabine + Fluorouracil + Leucovorin Regorafenib Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (AIO-KRK-0114) Recruiting 1
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Completed USA | CAN 7
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Completed USA 0
NCT02959437 Phase Ib/II Azacitidine + Epacadostat + Pembrolizumab Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) Terminated USA 2
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed USA 0
NCT02961283 Phase I ASN003 Study of ASN003 in Subjects With Advanced Solid Tumors Terminated USA 0
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Active, not recruiting USA 0
NCT02965417 Phase II SYM004 Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients Withdrawn 0
NCT02981524 Phase II Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer Completed USA 0
NCT02982694 Phase II Atezolizumab + Bevacizumab Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer Terminated 4
NCT02983578 Phase II AZD9150 + Durvalumab AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer Active, not recruiting USA 0
NCT02991196 Phase I DS-8273a + Nivolumab Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer Terminated USA 0
NCT02992912 Phase II Atezolizumab Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) Recruiting 1
NCT03005002 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver Completed USA 0
NCT03018405 Phase Ib/II NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Unknown status USA 1
NCT03031691 Phase I Brontictuzumab + Trifluridine A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer Completed USA 0
NCT03035279 Phase I SC-006 A Study of SC-006 in Subjects With Advanced Cancer Terminated USA 0
NCT03050814 Phase II Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 Completed USA 0
NCT03087591 Phase I APN401 APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03099486 Phase II Fluorouracil + Leucovorin + Regorafenib Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC Suspended USA 0
NCT03101475 Phase II Durvalumab + Tremelimumab Synergism of Immunomodulation and Tumor Ablation (ILOC) Active, not recruiting 6
NCT03122509 Phase II Durvalumab + Tremelimumab A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer Completed USA 0
NCT03184870 Phase Ib/II BMS-813160 + Fluorouracil + Irinotecan + Leucovorin BMS-813160 + Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel BMS-813160 A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 4
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Active, not recruiting USA | CAN 5
NCT03189030 Phase I pLADD Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer Terminated USA 0
NCT03203525 Phase I Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Doxorubicin + Temsirolimus Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer Recruiting USA 0
NCT03206073 Phase Ib/II Durvalumab + Tremelimumab Durvalumab A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Active, not recruiting USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting 9
NCT03215264 Phase Ib/II Entinostat + Hydroxychloroquine + Regorafenib Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer Completed USA 0
NCT03223779 Phase Ib/II Trifluridine Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer Recruiting USA 0
NCT03234712 Phase I ABBV-321 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands Completed USA 2
NCT03239145 Phase I Pembrolizumab + Trebananib Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor Active, not recruiting USA 0
NCT03256344 Phase I Atezolizumab + Talimogene laherparepvec Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases Active, not recruiting USA 5
NCT03259867 Phase II Nivolumab Pembrolizumab Combination of TATE and PD-1 Inhibitor in Liver Cancer Recruiting USA 0
NCT03263429 Phase Ib/II Irinotecan + Panitumumab + Telaglenastat Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer Recruiting USA 0
NCT03265080 Phase I ADXS-NEO Expressing Personalized Tumor Antigens Study Active, not recruiting USA 0
NCT03271047 Phase Ib/II Binimetinib + Ipilimumab + Nivolumab Binimetinib + Nivolumab Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation Completed USA 4
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting USA | CAN 6
NCT03290937 Phase I Cetuximab + Irinotecan + Utomilumab Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer Active, not recruiting USA 0
NCT03307603 Phase Ib/II Nivolumab + Yttrium-90 microsphere therapy Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer Withdrawn 0
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting USA 0
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting USA 0
NCT03340558 Phase II Atezolizumab Atezolizumab + Cobimetinib Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer (ATELIER) Withdrawn USA 0
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Terminated USA 0
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Terminated USA | CAN 0
NCT03374254 Phase I Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Binimetinib + Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651) Active, not recruiting USA | CAN 0
NCT03391232 Phase I PolyPEPI1018 Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO) Completed USA 1
NCT03403634 Phase I Celecoxib + Interferon alpha-2b + Rintatolimod Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver Active, not recruiting USA 0
NCT03407976 Phase Ib/II Pembrolizumab + Rivoceranib Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies Terminated USA 0
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Active, not recruiting USA 3
NCT03414983 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8) Active, not recruiting USA | CAN 3
NCT03415126 Phase I ASN007 A Study of ASN007 in Patients With Advanced Solid Tumors Completed USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Recruiting USA 3
NCT03428126 Phase II Durvalumab + Trametinib Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer Active, not recruiting USA 0
NCT03428958 Phase I A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment Recruiting USA 2
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Active, not recruiting USA 0
NCT03439462 Phase Ib/II Bevacizumab + Fluorouracil + Leucovorin + Nab-rapamycin + Oxaliplatin ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer Recruiting USA 0
NCT03446157 Phase II Cetuximab + Palbociclib Palbociclib and Cetuximab in Metastatic Colorectal Cancer Recruiting USA 0
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Recruiting USA 1
NCT03457896 Phase II Cetuximab + Neratinib Neratinib + Trastuzumab Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status Recruiting USA 0
NCT03473925 Phase II Navarixin + Pembrolizumab Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Completed USA | CAN 3
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting 1
NCT03476681 Phase I NEO-201 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting USA 0
NCT03485209 Phase II Tisotumab vedotin-tftv Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Recruiting USA | CAN 5
NCT03520946 Phase III Ramucirumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS) Recruiting 1
NCT03526835 Phase I MCLA-158 A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Unknown status USA 3
NCT03530267 Phase II Fluorouracil + Leucovorin + Oxaliplatin Aflibercept + Fluorouracil + Leucovorin Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (ELDERLY) Recruiting 1
NCT03531632 Phase Ib/II MGD007 + Retifanlimab MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03547999 Phase II Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin CV301 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC Active, not recruiting USA 0
NCT03549338 Phase II Modotuximab Futuximab SYM004 Sym004 Versus Futuximab or Modotuximab in Patients With mCRC Terminated USA 3
NCT03555149 Phase Ib/II Atezolizumab Atezolizumab + Isatuximab Atezolizumab + Bevacizumab + PGG beta-glucan A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) Recruiting USA 6
NCT03563157 Phase Ib/II Aldoxorubicin + ALT-803 + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Oxaliplatin + Regorafenib + Trastuzumab Regorafenib QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine Active, not recruiting USA 0
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Completed USA 0
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Completed USA | CAN 1
NCT03616574 Phase I CA102N CA102N + Trifluridine-tipiracil hydrochloride First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors Enrolling by invitation USA 0
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting USA 1
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA 1
NCT03631407 Phase II Pembrolizumab + Vicriviroc Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) Completed USA | CAN 0
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Active, not recruiting USA 1
NCT03656718 Phase Ib/II Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Recruiting USA 10
NCT03657641 Phase Ib/II Pembrolizumab + Regorafenib Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer Recruiting USA 0
NCT03658772 Phase I Grapiprant + Pembrolizumab Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer Recruiting USA 0
NCT03661632 Phase Ib/II BMS-986310 + Nivolumab An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA | CAN 1
NCT03668431 Phase II Dabrafenib + Spartalizumab + Trametinib Dabrafenib + Trametinib + PDR001 In Colorectal Cancer Recruiting USA 0
NCT03693170 Phase II Binimetinib + Cetuximab + Encorafenib Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC) Active, not recruiting USA 8
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated USA 0
NCT03714958 Phase I HDM201 + Trametinib Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD) Recruiting 1
NCT03720678 Phase I AB928 + Fluorouracil + Leucovorin + Oxaliplatin A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies Completed USA 1
NCT03724071 Phase Ib/II Flucytosine + TG6002 Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. Recruiting 3
NCT03735628 Phase Ib/II Copanlisib + Nivolumab An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Recruiting USA 0
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Recruiting USA | CAN 0
NCT03785210 Phase II Nivolumab + Tadalafil + Vancomycin Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers Recruiting USA 0
NCT03791398 Phase Ib/II Nivolumab + ONC201 BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC (379) Active, not recruiting USA 0
NCT03792724 Phase Ib/II Nivolumab + Urelumab Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) Not yet recruiting 1
NCT03795311 Phase Ib/II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3) (FOLFIRINOX3) Recruiting 1
NCT03796884 Phase II Linaclotide Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer Recruiting USA 0
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Recruiting USA | CAN 15
NCT03798626 Phase I Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052 Paclitaxel + Ramucirumab + XOMA 052 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052 Cabozantinib + XOMA 052 Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers Recruiting USA | CAN 16
NCT03802747 Phase I Durvalumab + Tremelimumab Durvalumab Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases Withdrawn 0
NCT03819387 Phase I NBF-006 A Study of NBF-006 in Non-Small Cell Lung,Pancreatic, or Colorectal Cancer Recruiting USA 0
NCT03829462 Phase III Regorafenib Irinotecan + Regorafenib Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI) Recruiting 1
NCT03844620 Phase II Regorafenib Trifluridine-tipiracil hydrochloride Regorafenib + Trifluridine-tipiracil hydrochloride Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer Recruiting USA 0
NCT03844750 Phase II Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery Recruiting USA 0
NCT03851614 Phase II Cediranib + Durvalumab Durvalumab + Olaparib Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) Active, not recruiting CAN 0
NCT03865082 Phase II IMO-2125 + Ipilimumab + Nivolumab Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) Recruiting USA 0
NCT03871959 Phase I Debio 1143 + Pembrolizumab Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (CATRIPCA) Recruiting 1
NCT03875313 Phase Ib/II Talazoparib + Telaglenastat Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Terminated USA 0
NCT03879811 Phase II Nivolumab Temozolomide Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer Withdrawn 0
NCT03891953 Phase I DKY709 DKY709 + Spartalizumab Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. Recruiting USA 5
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA 4
NCT03947385 Phase Ib/II IDE196 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Recruiting USA 1
NCT03953235 Phase Ib/II GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens Recruiting USA 0
NCT03965845 Phase Ib/II Palbociclib + Telaglenastat A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Active, not recruiting USA 0
NCT03970382 Phase I NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Recruiting USA 0
NCT03981614 Phase II Trifluridine-tipiracil hydrochloride Binimetinib + Palbociclib Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer Active, not recruiting USA 0
NCT03983993 Phase II Niraparib + Panitumumab Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect) Recruiting USA 0
NCT03990233 Phase I Effi-DEM BI 754091 + Effi-DEM A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours Recruiting 2
NCT04000529 Phase I Spartalizumab + TNO155 Ribociclib + TNO155 Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies Recruiting USA 8
NCT04008030 Phase III Nivolumab Fluorouracil + Irinotecan + Leucovorin Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab Ipilimumab + Nivolumab A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)) Recruiting USA | CAN 22
NCT04034459 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116) Recruiting 1
NCT04041310 Phase I GAd-209-FSP + MVA-209-FSP Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors Active, not recruiting USA 0
NCT04042480 Phase I SGN-CD228A A Study of SGN-CD228A in Advanced Solid Tumors Recruiting USA 4
NCT04046445 Phase Ib/II ATP128 + BI 754091 ATP128 Phase 1b Study to Evaluate ATP128, With or Without BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01) Recruiting USA 2
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting USA 1
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Recruiting USA 0
NCT04069026 Phase I BAY2416964 A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer Recruiting USA | CAN 4
NCT04072198 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (NIVACOR) Recruiting 1
NCT04073615 Phase Ib/II Rivoceranib + Trifluridine-tipiracil hydrochloride Rivoceranib Trifluridine-tipiracil hydrochloride Phase 1b/2 Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer Recruiting USA 0
NCT04083599 Phase Ib/II GEN1042 GEN1042 Safety Trial in Subjects With Malignant Solid Tumors Recruiting USA 4
NCT04096417 Phase II Pemigatinib Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations Recruiting USA 0
NCT04108481 Phase Ib/II Durvalumab Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C) Recruiting USA 0
NCT04117087 Phase I Ipilimumab + Nivolumab + Poly ICLC Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer Recruiting USA 0
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Completed USA 0
NCT04140526 Phase Ib/II ONC-392 ONC-392 + Pembrolizumab Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Recruiting USA 0
NCT04145193 Phase II Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Monalizumab + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC Withdrawn 0
NCT04164069 Phase I Bevacizumab + Dasatinib + Fluorouracil + Leucovorin + Oxaliplatin Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab Recruiting USA 0
NCT04166383 Phase II Nivolumab + VB-111 VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) Recruiting USA 0
NCT04172597 Phase II Poziotinib A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies Recruiting USA 0
NCT04189055 Phase II Cetuximab + Irinotecan Cetuximab Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL) Recruiting 1
NCT04194034 Phase Ib/II Flucytosine + TG6002 Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer Recruiting 2
NCT04244552 Phase I ATRC-101 First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies Recruiting USA 0
NCT04246671 Phase Ib/II TAEK-VAC-HerBy TAEK-VAC-HerBy + unspecified ERBB2 antibody + unspecified immune checkpoint inhibitor Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients Recruiting USA 0
NCT04249843 Phase I BGB3245 Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors Recruiting USA 1
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Recruiting USA 2
NCT04270864 Phase I IMO-2125 + Ipilimumab + Nivolumab Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers (PRIMO) Active, not recruiting 1
NCT04301011 Phase Ib/II TBio-6517 Pembrolizumab + TBio-6517 Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors (RAPTOR) Recruiting USA 0
NCT04330664 Phase Ib/II Adagrasib + TNO155 Phase 1/2 Study in Patients With Cancer Having a KRAS G12C Mutation Recruiting USA 0
NCT04332653 Phase Ib/II NT-I7 + Pembrolizumab NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60) Recruiting USA 0
NCT04338685 Phase I RO7119929 + Tocilizumab A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases Recruiting USA | CAN 5
NCT04344795 Phase I TPST-1495 Pembrolizumab + TPST-1495 Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors Recruiting USA 0
NCT04363242 Phase I SYN125 SYN004 + SYN125 A Study to Find the Maximum Tolerated Dose of SYN125 in People With Advanced Colorectal and Head and Neck Cancer Recruiting USA 0
NCT04381650 Phase Ib/II Pembrolizumab + TAK-981 A Safety and Efficacy Study of TAK-981 Plus Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT04421820 Phase I BOLD-100 + Fluorouracil + Leucovorin + Oxaliplatin BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours Recruiting CAN 0
NCT04425239 Phase II Fluorouracil + Irinotecan + Leucovorin + Panitumumab Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE) Active, not recruiting 1
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04430738 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers Recruiting USA 0
NCT04432857 Phase I E7046 + Pembrolizumab AN0025 and Pembrolizumab Combination in Advanced Solid Tumors Recruiting USA 1
NCT04449874 Phase I Atezolizumab + GDC-6036 Bevacizumab + GDC-6036 Cetuximab + GDC-6036 Erlotinib + GDC-6036 GDC-6036 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation Recruiting USA | CAN 14
NCT04450836 Phase II Regorafenib + Trifluridine-tipiracil hydrochloride Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (SOREGATT) Recruiting 1
NCT04468607 Phase I BLYG8824A A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer Recruiting USA 2
NCT04488003 Phase II Ulixertinib Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Recruiting USA 0
NCT04505839 Phase I STP1002 First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors Recruiting USA 0
NCT04508140 Phase II BO-112 + Pembrolizumab Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis Recruiting 3
NCT04511039 Phase I Talazoparib + Trifluridine-tipiracil hydrochloride Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer Recruiting USA 0
NCT04513951 Phase II Avelumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (AVETRIC) Recruiting 1
NCT04515394 Phase II Cetuximab + Tepotinib Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification Recruiting USA 7
NCT04535401 Phase I BAY1895344 + Fluorouracil + Irinotecan + Leucovorin Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines Recruiting USA 0
NCT04585035 Phase Ib/II D-1553 Study to Evaluate D-1553 in Subjects With Solid Tumors Recruiting USA 3
NCT04587128 Phase II Cetuximab Cetuximab + Irinotecan Panitumumab Irinotecan + Panitumumab Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC Recruiting USA 0
NCT04592653 Phase II ALKS 4230 + Pembrolizumab A Study of ALKS 4230 on the Tumor Microenvironment (ARTISTRY-3) Recruiting USA 0
NCT04595266 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + unspecified EGFR antibody Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + unspecified EGFR antibody Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (LIVERPEARL) Recruiting 1
NCT04602117 Phase I Paclitaxel + Trastuzumab Duocarmazine Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Recruiting USA 0
NCT04607421 Phase III Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Encorafenib Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER) Recruiting USA 10
NCT04609579 Phase I SNX281 Pembrolizumab + SNX281 Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA 0
NCT04616196 Phase Ib/II Cetuximab + NKTR-255 A Phase 1b/2 Study of NKTR 255 in Combination With Cetuximab in Solid Tumors Recruiting USA 0
NCT04622774 Phase I IMGC936 First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04645797 Phase I APR003 A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions Recruiting USA 0
NCT04659382 Phase II Atezolizumab + Bevacizumab + Capecitabine + Oxaliplatin Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (SIRTCI) Recruiting 1
NCT04665921 Phase I SGN-STNV A Study of SGN-STNV in Advanced Solid Tumors Recruiting USA | CAN 2
NCT04701476 Phase II Pembrolizumab + Tirapazamine TATE and Pembrolizumab (MK3475) in mCRC and NSCLC Recruiting USA 1
NCT04704661 Phase I Ceralasertib + Trastuzumab deruxtecan Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Recruiting USA 0
NCT04705818 Phase II Durvalumab + Tazemetostat Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) Recruiting 1
NCT04708470 Phase Ib/II Entinostat + M7824 + NHS-IL12 Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer Suspended USA 0
NCT04714983 Phase I DNX-2440 DNX-2440 for Resectable Colorectal Liver Metastasis Recruiting USA 0
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04761614 Phase I Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Riluzole Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Not yet recruiting USA 0
NCT04776655 Phase III Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb) Recruiting 1
NCT04787341 Phase II Regorafenib Panitumumab PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE) Recruiting 1
NCT04795661 Phase II Pembrolizumab Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) Not yet recruiting 1
NCT04800822 Phase I PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 PF-07284892 in Participants With Advanced Solid Tumors Recruiting USA 0
NCT04836195 Phase I PCLX-001 Phase I Trial of PCLX-001 in B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies Recruiting CAN 0
NCT04837196 Phase Ib/II ASP7517 + Pembrolizumab ASP7517 Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen Recruiting USA 0
NCT04854434 Phase II Trifluridine-tipiracil hydrochloride Pembrolizumab + Selinexor Selinexor A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations Recruiting USA 0
NCT04870034 Phase I Binimetinib + Palbociclib Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer Not yet recruiting USA 0
NCT04892017 Phase I DCC-3116 DCC-3116 + Trametinib A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors. Recruiting USA 0
NCT04895722 Phase II MK-1308A Pembrolizumab Evaluation of Pembrolizumab (MK-3475) or Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008) Recruiting USA 8
NCT04943900 Phase I BMS-986416 + Nivolumab BMS-986416 A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors Not yet recruiting USA | CAN 0
NCT04958239 Phase I BI 754091 + BI 765179 BI 765179 A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Recruiting USA 2
NCT04973163 Phase I BI 1823911 + Midazolam BI 1701963 + BI 1823911 A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation Recruiting USA 1
NCT04976634 Phase II Belzutifan + Lenvatinib + Pembrolizumab Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Recruiting USA 2
NCT04989387 Phase I INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 Study of INCA 0186 in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT05001282 Phase Ib/II ELU001 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) Recruiting USA 0
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 0
NCT05039177 Phase Ib/II ERAS-007 + Palbociclib Cetuximab + Encorafenib + ERAS-007 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) Recruiting USA 0
NCT05061017 Phase II Cyclophosphamide + Nivolumab + PG545 Nivolumab + PG545 Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) Not yet recruiting USA 0
NCT05062317 Phase II Capecitabine Leucovorin Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases Not yet recruiting USA 0